Contact us

By email : Bernard Vanhove

Academic partnerships aimed at scientific collaboration, and financial support to conduct research programs

OSE Immunotherapeutics benefits from an international network that offers access to the best experts in immunotherapy and transplantation, due to historic academic relationships.

Partnerships in basic research are currently conducted:

  • In Europe with the European Center for Sciences in Transplantation and Immunotherapy (CESTI) (which brings together the clinical teams of the University Hospital Institute and the teams of the INSERM Center for Research in Transplantation and Immunology – CRTI – INSERM 1UMR064), the Regional University Hospital and the University of Nantes, other French CNRS or INSERM teams, the « Children’s Cancer Research Institute » of Vienna (Austria), the “Biomedical Primate Research Center” in Netherlands and the Oxford University,
  • In the U.S. with the Maryland University in Baltimore and the « Ben Towne Center for Childhood Cancer Research » in Seattle (Washington).

This international network of excellence has resulted in promising data having been published in key scientific publications, resulting in increased visibility of the company’s achievements (Poirier et al. Science Translational Médicine 2010).

OSE Immunotherapeutics is supported by major institutional organizations : Pays de la Loire Territoires d’Innovation, Atlanpole Biothérapies, Bpifrance, and by national funding : « Prime d’aménagement du territoire », a funding for regional development.

OSE-127 (Effi-7), developed for the treatment of autoimmune diseases and transplantation through the consortium EFFIMab

OSE-127 (Effi-7) is a humanized monoclonal antibody targeting CD 127 receptor, the alpha chain of the Interleukin 7 receptor (IL-7R), with proof of concept confirmed in vivo in several auto-immune models. OSE-127 is being developed as part of the program EFFIMab for the treatment of hemorrhagic colitis and T-cell acute lymphoblastic leukemia.

The EFFIMab consortium, led by OSE Immunotherapeutics, includes the University Hospital of Nantes and the company PxTherapeutics. It is co-financed by Bpifrance with 9.5M€ in funding (for a total amount of 20M€) in the context of aid for Strategic Industrial Innovation (ISI), and has been awarded the “Atlanpole Biotherapies” label.

TRIAD (Tolerance Restoration in Autoimmune Diseases), an international project supported by the European Commission

TRIAD is a collaborative project supported by the European program, FP7-Health 2011 and is based on an innovative concept for the treatment of autoimmune diseases (including rheumatoid polyarthritis, multiple sclerosis, type 1 diabetes, psioriasis, uveitis and arteriosclerosis) using the activity of FR104. This international consortium is composed of the university-affiliated hospital of Nantes (« Centre Universitaire Hospitalier de Nantes »), the INSERM, the Oxford University, the Glasgow University, the Biomedical Primate Research Centre (Netherlands) and the Albert Einstein Israeli Institute for Education and Research (Brasil).